Dr. Katrin Küchler
About Dr. Katrin Küchler
Dr. Katrin Küchler is a Medical Scientific Liaison Oncology at Daiichi Sankyo Deutschland GmbH and an intern at Bristol-Myers Squibb, with expertise in molecular tumor research and cellular/molecular biology.
Current Role at Daiichi Sankyo
Dr. Katrin Küchler currently works at Daiichi Sankyo Deutschland GmbH as a Medical Scientific Liaison Oncology. She started this role in March 2017. Her responsibilities include facilitating communication between the company and the medical community in the field of oncology. She is based in Berlin und Umgebung, Deutschland, contributing her expertise in molecular tumor research and cellular/molecular biology to support the company's initiatives.
Internship at Bristol-Myers Squibb
Dr. Katrin Küchler is currently also working as an intern at Bristol-Myers Squibb in the Munich area, Deutschland. While specific details of her internship duties are not disclosed, she is gaining practical experience and expanding her knowledge in the pharmaceutical industry, further honing her skills in the research and development sector.
Education and Degrees
Dr. Katrin Küchler pursued her higher education at Friedrich-Alexander-Universität Erlangen-Nürnberg. She completed her Master of Science (M.Sc.) in Zell-/Zellularbiologie und Molekularbiologie from 2010 to 2012. Subsequently, she achieved her Dr rer. nat., specializing in molekulare Tumorforschung, from 2012 to 2016. Her educational background has provided her with a strong foundation in molecular and cellular biology, which she applies in her professional roles.
Research Expertise in Oncology
Dr. Katrin Küchler possesses in-depth expertise in molecular tumor research and cellular/molecular biology. Her academic and professional experiences have equipped her with a thorough understanding of these fields, making her a valuable asset in oncology-related scientific research and communication. She applies this knowledge in her current role at Daiichi Sankyo Deutschland GmbH and during her internship at Bristol-Myers Squibb.